Binder E, Lange O, Edlinger M, Meraner D, Abt D, Moser C, Steichen E, Hofer S E
Department of Pediatrics, Medical University of Innsbruck, Innsbruck.
Department of Medical Statistics, Informatics and Health Economics, Medical University of Innsbruck, Innsbruck.
Exp Clin Endocrinol Diabetes. 2015 Apr;123(4):260-4. doi: 10.1055/s-0034-1394381. Epub 2015 Jan 21.
The incidence of type 1 diabetes is rising, particularly in young infants. The treatment with continuous subcutaneous insulin infusion (CSII) offers certain benefits and has gained popularity. Insulin-pump therapy could be associated with cutaneous-adverse effects. The purpose of our study was to investigate the frequency and characterization of skin-related complications in patients with CSII.
In a single center setting, 54 patients (28 male, 26 female) on CSII therapy aged between 3 and 20 years participated in our study. Data including duration of diabetes, duration of CSII, pump model, catheter material, frequency of catheter switch and hygiene procedures at time of puncture were collected through a standardized questionnaire and photographs of affected areas of the skin were made. Statistical analysis was done to verify an association with gender, patients' age, HbA1c values, and body mass index.
Our observation revealed skin complications at the site of catheter insertion in 43% (8 f, 15 m) of our patients. A frequent occurrence of scars (24%, 6 f, 7 m), lipohypertrophic areas (20%, 4 f, 7 m) and eczema (11%, 1 f, 5 m) was observed. Furthermore, 6% (1 f, 2 m) showed changes in pigmentation and 6% (1 f, 2 m) lipoatrophy. The catheter localization had to be switched due to skin-complications in 24% (6 f, 7 m) whereas none of our patients discontinued insulin-pump therapy.
Skin-related complications during CSII are frequent and regular examination of the insertion sites is crucial. To verify the occurrence of lipoatrophy associated with insulin pump therapy - an otherwise rare complication - larger studies would be needed.
1型糖尿病的发病率正在上升,尤其是在幼儿中。持续皮下胰岛素输注(CSII)治疗具有一定益处并已得到广泛应用。胰岛素泵治疗可能会伴有皮肤不良反应。我们研究的目的是调查接受CSII治疗的患者皮肤相关并发症的发生率及特征。
在单中心环境下,54例年龄在3至20岁之间接受CSII治疗的患者(28例男性,26例女性)参与了我们的研究。通过标准化问卷收集包括糖尿病病程、CSII治疗时间、泵型号、导管材料、导管更换频率以及穿刺时的卫生程序等数据,并拍摄皮肤受累区域的照片。进行统计分析以验证与性别、患者年龄、糖化血红蛋白值和体重指数之间的关联。
我们的观察发现,43%(8例女性,15例男性)的患者在导管插入部位出现皮肤并发症。观察到瘢痕频繁出现(24%,6例女性,7例男性)、脂肪增生区域(20%,4例女性,7例男性)和湿疹(11%,1例女性,5例男性)。此外,6%(1例女性,2例男性)出现色素沉着变化,6%(1例女性,2例男性)出现脂肪萎缩。24%(6例女性,7例男性)的患者因皮肤并发症而不得不更换导管位置,而我们的患者中无人停止胰岛素泵治疗。
CSII治疗期间皮肤相关并发症很常见,定期检查插入部位至关重要。要证实与胰岛素泵治疗相关的脂肪萎缩(一种罕见的并发症)的发生,还需要进行更大规模的研究。